New: Biden White House Executive Order opposes change in Bayh-Dole March-In regulations. (KEI has an email list to discuss this issue here: http://lists.keionline.org/mailman/listinfo/bayh-dole-regulations_lists.keionline.org) The Department of Commerce’s National Institute of Standards and Technology (NIST) published on January 4, 2021, a… Continue Reading
Based on press releases and additional publicly-available information, KEI is building a dataset with a non-exhaustive list of deals that involve technology transfer and outsourcing of COVID-19 vaccines manufacturing. As of February 19, 2021, the dataset includes observations for over… Continue Reading
On Monday, 15 February 2021, the World Trade Organization’s General Council, “agreed by consensus to select Ngozi Okonjo-Iweala of Nigeria as the organization’s seventh Director-General” (Source: History is made: Ngozi Okonjo-Iweala chosen as Director-General, 15 February 2021). Dr Ngozi is… Continue Reading
(More on the USTR Special 301. link) Attached are links to several of the industry submissions for the 2021 USTR Special 301 list. The Docket: USTR-2020-0041 PhRMA 2021 Special 301 Review Comment, and Correction to Comment BIO 2021 Special 301… Continue Reading
On February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer” to Ziopharm Oncology, Inc. (Ziopharm). The… Continue Reading
On Tuesday February 9, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Certain Fusion Proteins and Their Use for the Treatment… Continue Reading
KEI roundtable on pathways to scale up manufacturing capacity for COVID-19 vaccines Friday, 19 February 2021 14h00 UTC to 16h00 UTC 15h00 CET to 17h00 CET 09h00 EST to 11h00 EST On Friday, 19 February 2021, KEI will host a… Continue Reading
KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading